SCI Pharmtech, Inc.
TAI: 4119.TW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Wen-Chih Chou
- Employees
- 202
- Headquarters
- Taoyuan City, Taiwan
- IPO year
- 2004
- Market cap
- NT$5.6B
- Website
- https://www.sci-pharmtech.com.tw
Loading 4119…
Loading profile data…Frequently asked questions about 4119
What does SCI Pharmtech, Inc. (4119.TW) do?
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxo...
Where does 4119.TW trade?
SCI Pharmtech, Inc. (4119.TW) trades on the Taiwan Stock Exchange.
What sector is 4119.TW in?
SCI Pharmtech, Inc. (4119.TW) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of SCI Pharmtech, Inc.?
Wen-Chih Chou is the chief executive officer of SCI Pharmtech, Inc. (4119.TW).
Where is SCI Pharmtech, Inc. headquartered?
SCI Pharmtech, Inc. is headquartered in Taiwan.
Does 4119.TW pay a dividend?
Yes — SCI Pharmtech, Inc. (4119.TW) paid a trailing twelve-month dividend of TWD 1.50 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4119.TW go public?
SCI Pharmtech, Inc. (4119.TW) completed its initial public offering in 2004.